[The expression of nm23-H1 genes with clinical prognosis in endometrial carcinoma]

Abstract

Objective: To study the expression of nm23-H1 gene in endometrial carcinoma and its relationships between the clinicopathological parameter and prognosis of endometrial carcinoma.

Methods: The endometrial specimens of 60 cases with endometrial carcinoma were studied retrospectively by immunohistochemical stainings.

Results: The positive expression rate of nm23-H1 gene in endometrial carcinoma was 55.0% (33/60). The positive rate of nm23-H1 in early endometrial carcinoma was significantly higher than that in advanced cases (65.9% and 25.0%, respectively, P < 0.05). Positive rates in the well and moderately differentiated endometrial carcinoma were also higher than those of poorly differentiated (66.7%, 63.6%, 29.4%, P < 0.05). 20.0% of the cases with and 64.9% of the cases without lymph node metastasis showed positive for nm23-H1 (P < 0.05). The expression of nm23-H1 was not correlated with histological type, myometrial invasion, estrogen receptor and progesterone receptor. The survival rate of patients with nm23-H1 expression was significantly higher than that of patients without nm23-H1 expression. The 5-year survival rate was 90.5% and 55.3% respectively (P < 0.05).

Conclusion: nm23-H1 gene may play a role in the inhibitory effect on the development and the lymph node metastasis of endometrial carcinoma, and may be related to be prognosis of endometrial carcinoma.